Suven Pharmaceuticals Limited

NSEI:SUVENPHAR Voorraadrapport

Marktkapitalisatie: ₹324.4b

Suven Pharmaceuticals Toekomstige groei

Future criteriumcontroles 2/6

Suven Pharmaceuticals zal naar verwachting zijn omzet verhogen met 25.5% per jaar.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Pharmaceuticals winstgroei17.7%
Inkomstengroei25.5%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Low

Laatst bijgewerkt15 Nov 2024

Recente toekomstige groei-updates

Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report

Jun 11
Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report

Recent updates

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Dec 15
These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)

Aug 03
Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

May 12
Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected

Mar 26
Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected

Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching

Mar 07
Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Nov 30
These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?

Sep 03
Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?

Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly

Aug 04
Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly

Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report

Jun 11
Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report

With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting

Apr 13
With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Mar 08
Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?

Feb 08
Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?

Winst- en omzetgroeiprognoses

NSEI:SUVENPHAR - Toekomstschattingen van analisten en financiële gegevens uit het verleden (INR Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
3/31/202614,8004,410N/A4,9701
3/31/202513,210N/AN/A3,8101
9/30/20249,6122,4311,8852,838N/A
6/30/20249,3452,405N/AN/AN/A
3/31/202410,5143,0033,0673,585N/A
12/31/202311,6783,709N/AN/AN/A
9/30/202313,0174,3183,1304,318N/A
6/30/202313,4914,243N/AN/AN/A
3/31/202313,4034,1131,7134,572N/A
12/31/202213,3483,790N/AN/AN/A
9/30/202213,7264,3132,5224,787N/A
6/30/202213,9524,563N/AN/AN/A
3/31/202213,2024,5382,5483,300N/A
12/31/202112,1554,453N/AN/AN/A
9/30/202110,9893,9882,5613,465N/A
6/30/202110,3533,759N/AN/AN/A
3/31/202110,0973,6232,7173,825N/A
12/31/20209,3533,534N/AN/AN/A
9/30/20208,3912,9772,5183,843N/A
6/30/20208,7463,166N/AN/AN/A
3/31/20208,3383,1703,0394,069N/A
3/31/20199,0682,623-1531,210N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van SUVENPHAR boven de spaarquote ( 6.7% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van SUVENPHAR naar verwachting sneller zal groeien dan de markt Indian

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van SUVENPHAR naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: De omzet van SUVENPHAR ( 25.5% per jaar) zal naar verwachting sneller groeien dan de markt Indian ( 10.5% per jaar).

Hoge groei-inkomsten: De omzet van SUVENPHAR ( 25.5% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van SUVENPHAR naar verwachting over 3 jaar hoog zal zijn


Ontdek groeibedrijven